Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 194 mg) |
| Drug Class | Antibacterials |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- To treat travelers’ diarrhea caused by non-invasive strains of Escherichia coli in adults.
Summary
- Rifamycin (Aemcolo) is indicated for the treatment of travelers’ diarrhea caused by non-invasive strains of Escherichia coli in adults.
- A total of 3 systematic reviews/meta-analyses were reviewed to gather information about this drug.
- Genetic variations in drug-metabolizing enzymes and transporter proteins contribute to the inter-individual variation observed with rifamycin pharmacokinetics, as per one review.
- Another study found that coadministration of rifamycins with anticoagulant and antiplatelet agents can impact their concentrations and efficacy due to induction activity on various drug transporting and metabolizing enzymes, suggesting potential risks when used together.
- The third review highlighted that certain antibiotics including rifamycins have high antimicrobial activity against Clostridium difficile infection, indicating its potential use beyond its current indication for treating E.coli-induced diarrhea.
- However, further controlled clinical studies are required to establish these relationships between genetic variations or antibiotic combinations with the pharmacokinetics and therapeutic outcomes associated with Rifamycin (Aemcolo).
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Aemcolo (rifamycin) Prescribing Information. | 2019 | RedHill Biopharma, Inc. Raleigh, NC |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review. | 2022 | Pharmacogenomics and Personalized Medicine |
| Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management. | 2022 | Pharmacotherapy |
| Susceptibilities of clinical Clostridium difficile isolates to antimicrobials: a systematic review and meta-analysis of studies since 1970. | 2018 | Clinical Microbiology and Infection |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. | 2022 | Gastroenterology |